<rss version="2.0"><channel><title>Yahoo! Finance: EPI.TO News</title><copyright>Copyright (c) 2017 Yahoo! Inc. All rights reserved.</copyright><link>http://finance.yahoo.com/q/h?s=epi.to</link><description>Latest Financial News for ESSA PHARMA INC</description><language>en-US</language><lastBuildDate>Wed, 14 Dec 2016 13:30:00 GMT</lastBuildDate><image><url>http://l.yimg.com/a/i/brand/purplelogo/uh/us/fin.gif</url><title>Yahoo! Finance: EPI.TO News</title><link>http://finance.yahoo.com/q/h?s=epi.to</link><width>144</width><height>45</height></image><item><title>ESSA Pharma Provides Business Update and Announces Fourth Quarter and Year Ended September 30, 2016 Financial Results</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-provides-business-announces-133000227.html</link><description>[CNW Group] - ESSA Pharma Provides Business Update and Announces Fourth Quarter and Year Ended September 30, 2016 Financial Results</description><guid isPermaLink="false">yahoo_finance/3210664562</guid><pubDate>Wed, 14 Dec 2016 13:30:00 GMT</pubDate></item><item><title>ESSA Pharma Provides Business Update and Announces Fourth Quarter and Year Ended September 30, 2016 Financial Results</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-provides-business-announces-133000425.html</link><description>[PR Newswire] - HOUSTON and VANCOUVER, Dec. 14, 2016 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX: EPI), a clinical stage pharmaceutical company focused on developing ...</description><guid isPermaLink="false">yahoo_finance/1885742710</guid><pubDate>Wed, 14 Dec 2016 13:30:00 GMT</pubDate></item><item><title>ESSA Secures US$10 Million Term Loan from Silicon Valley Bank</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-secures-us-10-million-133000448.html</link><description>[CNW Group] - ESSA Secures US$10 Million Term Loan from Silicon Valley Bank</description><guid isPermaLink="false">yahoo_finance/2789709029</guid><pubDate>Mon, 21 Nov 2016 13:30:00 GMT</pubDate></item><item><title>ESSA Secures US$10 Million Term Loan from Silicon Valley Bank</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-secures-us-10-million-133000369.html</link><description>[PR Newswire] - HOUSTON and VANCOUVER, Nov. 21, 2016 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on the development of small molecule drugs for the treatment of prostate cancer, announced that it has secured a US$10 million growth capital term loan facility from Silicon Valley Bank ("SVB" or the "Bank"). Under the loan and security agreement, the Company will initially draw down US$8 million and has a conditional option to receive an additional US$2 million (collectively, the "Term Loans"). The proceeds from the Term Loans will be used for the Company's future working capital needs.</description><guid isPermaLink="false">yahoo_finance/1117161473</guid><pubDate>Mon, 21 Nov 2016 13:30:00 GMT</pubDate></item><item><title>ESSA Pharma to present at Rodman &amp; Renshaw 18th Annual Global Investment Conference</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-present-rodman-renshaw-123600504.html</link><description>[CNW Group] - ESSA Pharma to present at Rodman &amp; Renshaw 18th Annual Global Investment Conference</description><guid isPermaLink="false">yahoo_finance/4241491667</guid><pubDate>Mon, 12 Sep 2016 12:36:00 GMT</pubDate></item><item><title>ESSA Pharma to present at Rodman &amp; Renshaw 18th Annual Global Investment Conference</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-present-rodman-renshaw-123600996.html</link><description>[PR Newswire] - HOUSTON, TX and VANCOUVER, Canada, Sept. 12, 2016 /PRNewswire/ - ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company") a clinical stage company focused on the development of small molecule drugs for the treatment of cancer, today announced David R. Parkinson, President and Chief Executive Officer will be presenting at the Rodman &amp; Renshaw 18th Annual Global Investment Conference in New York City on Tuesday September 13th at 11:15 AM Eastern Time at the Lotte New York Palace Hotel. Dr. Parkinson will provide a corporate overview of the Company's business and will be available for one-on-one meetings from September 12 &#8211; 13, 2016. ESSA's Chief Financial Officer, David S. Wood and ESSA's Chief Operating Officer, Peter Virsik, will be also in attendance. A live audio webcast of the presentation may be accessed by visiting http://wsw.com/webcast/rrshq26/epi and will be available at the Company's website(www.essapharma.com) after the conference.</description><guid isPermaLink="false">yahoo_finance/1511443884</guid><pubDate>Mon, 12 Sep 2016 12:36:00 GMT</pubDate></item><item><title>ESSA Pharma Inc. reports financial results for the third quarter June 30, 2016</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-financial-200000191.html</link><description>[PR Newswire] - HOUSTON, TX and VANCOUVER, Aug. 12, 2016 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) today reported financial results for the third quarter and three months ended June 30, 2016. Amounts, unless specified otherwise, are expressed in United States dollars and in accordance with International Financial Reporting Standards ("IFRS"). ESSA recorded a net loss of $3.9 million ($0.13 per common share) for the three months ended June 30, 2016, compared to a net loss of $4.9 million ($0.29 per common share) for the three months ended June 30, 2015. Research and Development ("R&amp;D") expenditures for the three month period were $3.4 million compared to $2.6 million for 2015. R&amp;D expenditures in the period are primarily related to manufacturing and clinical costs as the Company continues its work in the clinical development stage with respect to clinical candidate EPI-506.</description><guid isPermaLink="false">yahoo_finance/3641838387</guid><pubDate>Fri, 12 Aug 2016 20:00:00 GMT</pubDate></item><item><title>ESSA Pharma Inc. reports financial results for the third quarter June 30, 2016</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-financial-200000130.html</link><description>[CNW Group] - ESSA Pharma Inc. reports financial results for the third quarter June 30, 2016</description><guid isPermaLink="false">yahoo_finance/2895264434</guid><pubDate>Fri, 12 Aug 2016 20:00:00 GMT</pubDate></item><item><title>ESSA Names Peter Virsik as Executive Vice President &amp; Chief Operating Officer</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-names-peter-virsik-executive-121500154.html</link><description>[CNW Group] - ESSA Names Peter Virsik as Executive Vice President &amp; Chief Operating Officer</description><guid isPermaLink="false">yahoo_finance/50574886</guid><pubDate>Mon, 01 Aug 2016 12:15:00 GMT</pubDate></item><item><title>ESSA Names Peter Virsik as Executive Vice President &amp; Chief Operating Officer</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-names-peter-virsik-executive-121500020.html</link><description>[PR Newswire] - Mr. Virsik will be responsible for leading ESSA's overall business development and corporate strategy as the Company further advances its clinical development plan for the novel prostate cancer therapeutic EPI-506.</description><guid isPermaLink="false">yahoo_finance/570810290</guid><pubDate>Mon, 01 Aug 2016 12:15:00 GMT</pubDate></item><item><title>ESSA Pharma Inc. Reports Financial Results for the Second Quarter Ended March 31, 2016</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-financial-201500563.html</link><description>[CNW Group] - ESSA Pharma Inc. Reports Financial Results for the Second Quarter Ended March 31, 2016</description><guid isPermaLink="false">yahoo_finance/470368004</guid><pubDate>Fri, 13 May 2016 20:15:00 GMT</pubDate></item><item><title>ESSA Pharma Inc. Reports Financial Results for the Second Quarter Ended March 31, 2016</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-financial-201500067.html</link><description>[PR Newswire] - HOUSTON and VANCOUVER, May 13, 2016 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) today reported financial results for the second quarter and three months ended March 31, 2016. Amounts, unless specified otherwise, are expressed in United States dollars and in accordance with International Financial Reporting Standards ("IFRS"). Dr. David R. Parkinson was appointed as the company's President and Chief Executive Officer on January 7th, 2016, bringing significant drug development and business experience to the Company.</description><guid isPermaLink="false">yahoo_finance/1755382999</guid><pubDate>Fri, 13 May 2016 20:15:00 GMT</pubDate></item><item><title>ESSA Pharma Announces Closing of a Secondary Offering</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-announces-closing-secondary-000200885.html</link><description>[PR Newswire] - HOUSTON, TX and VANCOUVER, March 21, 2016 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) announced today that Eventide Funds purchased 370,566 Common Shares from each of Marianne Sadar and Raymond Andersen, both directors and officers of the Company, and 311,612 Common Shares from Robert Rieder, at a price of US$3.00 per Common Share. The Company did not receive any proceeds from the transaction.</description><guid isPermaLink="false">yahoo_finance/413139100</guid><pubDate>Tue, 22 Mar 2016 00:02:00 GMT</pubDate></item><item><title>ESSA Pharma Announces Closing of a Secondary Offering</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-announces-closing-secondary-000200740.html</link><description>[CNW Group] - ESSA Pharma Announces Closing of a Secondary Offering</description><guid isPermaLink="false">yahoo_finance/2318486430</guid><pubDate>Tue, 22 Mar 2016 00:02:00 GMT</pubDate></item><item><title>ESSA Pharma Announces Closing of US$5 Million Private Placement</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-announces-closing-us-235200974.html</link><description>[PR Newswire] - HOUSTON, TX and VANCOUVER, March 21, 2016 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of 1,666,666 common shares in the capital of the Company ("Common Shares") at US$3.00 per Common Share to Eventide Funds for gross proceeds of approximately US$5 million. The Company intends to use the net proceeds from the Private Placement for general corporate purposes, including funding research and development, preclinical and clinical expenses, and corporate costs.</description><guid isPermaLink="false">yahoo_finance/2725710669</guid><pubDate>Mon, 21 Mar 2016 23:52:00 GMT</pubDate></item><item><title>ESSA Pharma Announces Closing of US$5 Million Private Placement</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-announces-closing-us-235200433.html</link><description>[CNW Group] - ESSA Pharma Announces Closing of US$5 Million Private Placement</description><guid isPermaLink="false">yahoo_finance/3443670883</guid><pubDate>Mon, 21 Mar 2016 23:52:00 GMT</pubDate></item><item><title>ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-results-021500593.html</link><description /><guid isPermaLink="false">yahoo_finance/4069150026</guid><pubDate>Fri, 11 Mar 2016 02:15:00 GMT</pubDate></item><item><title>ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-results-021500824.html</link><description>[PR Newswire] - HOUSTON, TEXAS and VANCOUVER, BC, March 10, 2016 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) is pleased to announce the results of the votes on ...</description><guid isPermaLink="false">yahoo_finance/2641786499</guid><pubDate>Fri, 11 Mar 2016 02:15:00 GMT</pubDate></item><item><title>ESSA Pharma Inc. reports financial results for the first quarter ended December 31, 2015</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-financial-230000606.html</link><description /><guid isPermaLink="false">yahoo_finance/2322036769</guid><pubDate>Fri, 12 Feb 2016 23:00:00 GMT</pubDate></item><item><title>ESSA Pharma Inc. reports financial results for the first quarter ended December 31, 2015</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/essa-pharma-inc-reports-financial-230000135.html</link><description /><guid isPermaLink="false">yahoo_finance/2532768134</guid><pubDate>Fri, 12 Feb 2016 23:00:00 GMT</pubDate></item></channel></rss>